लोड हो रहा है...
Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
The incorporation of novel agents such as bortezomib and lenalidomide into initial therapy for multiple myeloma has improved the response rate of induction regimens. Also, these drugs are being increasingly used in the peri-transplant setting for transplant-eligible patients, and as part of consolid...
में बचाया:
| मुख्य लेखक: | |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2013
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3819933/ https://ncbi.nlm.nih.gov/pubmed/24135408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminoncol.2013.07.007 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|